- iInformed Consent will be sought for the main trial and qualitative studies (during internal pilot and at completion of the follow-up period) at Screening Visit 1
- iiPost Randomisation Telephone Review after 1 month (+/- 3 days) to review device usage and check device related technical issues have been addressed
- iiiSevere Exacerbation Reporting. Participants will report severe exacerbations to their local trial team as soon as possible throughout the follow-up period
- ivSerum Specific IgE only required if Skin Prick Tests not available
- vPost-Trial Provision Period refers to treatment with an active TLA device free of charge including filters and technical support over a 4 year period
- viAdult Carer / Partner participation in selected cases is entirely optional and will not influence participant’s eligibility for inclusion in the trial
- viiInstallation within 10 working days of Randomisation
- viiiDevice Exchange / Removal within 10 working days of last study visit or focus group involvement whichever comes last